ACE2 and infection: Targeting of the known ACE2 receptor by CRISPR-Cas9 led to a near-complete loss of infectivity (two-way ANOVA of ACE2 infection vs B2M control Bonferroni-corrected p-value < 0.001), despite these cells retaining very high expression of BSG (Fig. 4b).